M2care raises €26M backed by Bpifrance to launch 8 new health tech startups

M2care, a European healthtech venture studio, has closed €26 million in funding with backing from France’s state-owned investor Bpifrance. The fresh capital, anchored by the French Tech Accélération 2 (FTA2) fund under the France 2030 program, comes alongside support from existing investors Mérieux Développement, Institut NAOS des Sciences de la Vie, Crédit Agricole Centre-Est, and several family offices.

The funding gives M2care firepower to launch eight new healthcare projects, furthering its model of building startups at the intersection of academia, investors, and industry. The studio works hand in hand with founders, pairing them with a team of “entrepreneurs in residence” and a global network to spin lab-born ideas into real-world medical technologies.

M2care has already backed three companies that hint at its scope. Previa Medical is developing a digital device to predict and prevent medical emergencies in hospitals. TheraSonic is advancing ultrasound-based treatments for brain diseases. And Rhovica Neuroimaging is creating a catheter with integrated sensors to help emergency patients facing dangerous spikes in intracranial pressure.

With cardiology, dermatology, ophthalmology, and neurology as priority areas, the studio is preparing to launch a fourth project while mapping out the next wave of startups the new funding will support.

For Bpifrance, the move is part of a broader strategy to speed up the transfer of academic research into the market under France 2030. “By investing in M2care, we are reaffirming our commitment to strengthening our technological sovereignty in healthcare,” said Pierre Gillet, Investment Director at Bpifrance.

M2care’s leadership sees the raise as a turning point. “I am delighted that France 2030’s French Tech Acceleration 2 fund has invested in our studio. Bpifrance is a leading player whose strong support will help to bring healthcare innovations to patients and into the market,” said Florence Thueux, President of M2care. General Manager Carsten Laue added that the support will “help to create pioneering Healthtech startups.”

Founded by Mérieux Développement and CEA Investissement, M2care has positioned itself as a builder of early-stage healthtech companies with international reach. With €26 million now secured, the studio is betting on its ability to turn academic science into startups that reshape patient care.